No connection

Search Results

RADX vs RMTI

RADX
Radiopharm Theranostics Limited
BEARISH
Price
$4.58
Market Cap
$36.1M
Sector
Healthcare
AI Confidence
85%
RMTI
Rockwell Medical, Inc.
BEARISH
Price
$0.91
Market Cap
$36.0M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
RADX
--
RMTI
--
Forward P/E
RADX
-1.75
RMTI
13.05
P/B Ratio
RADX
1.43
RMTI
0.97
P/S Ratio
RADX
2.22
RMTI
0.52
EV/EBITDA
RADX
-413.38
RMTI
-9.4

Profitability

Gross Margin
RADX
-136.51%
RMTI
16.89%
Operating Margin
RADX
-423.75%
RMTI
-2.17%
Profit Margin
RADX
-286.16%
RMTI
-7.67%
ROE
RADX
-92.1%
RMTI
-15.28%
ROA
RADX
-28.33%
RMTI
-5.04%

Growth

Revenue Growth
RADX
154.5%
RMTI
-25.6%
Earnings Growth
RADX
--
RMTI
--

Financial Health

Debt/Equity
RADX
--
RMTI
0.34
Current Ratio
RADX
3.01
RMTI
3.98
Quick Ratio
RADX
3.0
RMTI
3.46

Dividends

Dividend Yield
RADX
--
RMTI
--
Payout Ratio
RADX
0.0%
RMTI
0.0%

AI Verdict

RADX BEARISH

RADX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation benchmarks like the Graham Number due to negative earnings. While the company shows impressive YoY revenue growth of 154.50% and maintains strong short-term liquidity (Current Ratio 3.01), these are overshadowed by a catastrophic negative gross margin of -136.51%. The stock is in a severe technical downtrend, having collapsed from a 52-week high of $16.25 to $4.58, suggesting a significant loss of investor confidence despite optimistic analyst price targets.

Strengths
Exceptional YoY revenue growth of 154.50%
Strong liquidity position with a Current Ratio of 3.01
Low Price-to-Sales ratio (2.22) relative to biotech peers
Risks
Negative gross margins indicate the cost of producing goods exceeds revenue
Severe operating losses with an operating margin of -423.75%
Extreme technical weakness (Technical Trend score 0/100)
RMTI BEARISH

RMTI exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across profitability and operational efficiency. Despite a strong current ratio of 3.98 and low debt-to-equity, the company is suffering from a significant revenue contraction of -25.60% YoY and consistent earnings misses (0/4 beats in the last year). The disconnect between the analyst target price of $3.00 and the actual fundamental decay, coupled with bearish insider selling, suggests a high-risk speculative profile.

Strengths
Strong short-term liquidity with a current ratio of 3.98
Low leverage with a Debt/Equity ratio of 0.34
Trading slightly below book value (P/B 0.97)
Risks
Severe revenue decline (-25.60% YoY and Q/Q)
Consistent failure to meet earnings estimates (Average surprise -80.56%)
Negative ROE (-15.28%) and negative profit margins

Compare Another Pair

RADX vs RMTI: Head-to-Head Comparison

This page compares Radiopharm Theranostics Limited (RADX) and Rockwell Medical, Inc. (RMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile